Have a personal or library account? Click to login
Long-term Survival of Patients with Breast Cancer and Brain Metastases: ‘The experience of the 2nd Oncology Department of Metropolitan Hospital and a brief review of the literature’ Cover

Long-term Survival of Patients with Breast Cancer and Brain Metastases: ‘The experience of the 2nd Oncology Department of Metropolitan Hospital and a brief review of the literature’

Forum of Clinical Oncology
Volume 6 (2015): Issue 1 (March 2015)
By: Aravantinou-Fatorou E,  Skarlos D,  Klouvas G,  Galani E and  Christodoulou C.  
Open Access
|Mar 2015

References

  1. [1] Frisk G, Svensson T, Backlund LM, Lidbrink E, Blomqvist P, Smedby KE. Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer. 2012 May 22;106:1850-3.10.1038/bjc.2012.163336412422531629
    Search in Google Scholar
  2. [2] Lang EF, Slater J. Metastatic brain tumor: Results of surgical and nonsurgical treatment. Surg. Clin. North Am. 44:865, 1964.
    Search in Google Scholar
  3. [3] Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist, 2003, 8, 398-410.10.1634/theoncologist.8-5-39814530493
    Search in Google Scholar
  4. [4] Rorive A, Colliggnon J, Martin M, Andre C, Jerusalem G, Coucke Ph. Cancer du Sein et Metastases cerebrales, Rev Med Liege 2011;66:5-6:299-305
    Search in Google Scholar
  5. [5] Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-3617.10.1200/JCO.2004.01.17515337811
    Search in Google Scholar
  6. [6] Chang EL, Lo S. Diagnosis and Management of Central Nervous Metastases from Breast cancer. The Oncologist 2003;8:398-410.10.1634/theoncologist.8-5-398
    Search in Google Scholar
  7. [7] McCormick B, Abramson DH. Ocular metastases. In:Harris JR, ed Disease of the Breast Philadelphia: Lippincott Williams &Wilkins,2000:889-891.
    Search in Google Scholar
  8. [8] Evans A, James J, Cornford E, Chan S, Burrell H, Pinder S, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol. 2004;16:345-349.10.1016/j.clon.2004.03.01215341438
    Search in Google Scholar
  9. [9] Scott B, Kesari S. Leptomeningeal metastases in breast cancer Am J Cancer Res. 2013; 3(2): 117-126.
    Search in Google Scholar
  10. [10] Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. International Breast Cancer Study Group (IBCSG) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann Oncol. 2006;17:935-944.10.1093/annonc/mdl06416603601
    Search in Google Scholar
  11. [11] Kennecke H, Yerushalmi R, Woods R, Cheang MCV, Voduc D, Speers CH et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol, 2010, 28, 3271-3277.10.1200/JCO.2009.25.982020498394
    Search in Google Scholar
  12. [12] Lin NU, Dieras V, Paul D, Lossingol D, Christodoulou Ch, Stemmler HJ et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-1459.10.1158/1078-0432.CCR-08-108019228746
    Search in Google Scholar
  13. [13] Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindther J, Collins J et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-944.10.1093/annonc/mdl064
    Search in Google Scholar
  14. [14] Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 696-704.10.1002/cncr.2204116826579
    Search in Google Scholar
  15. [15] Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol. 2004 Nov;15:1640-4.10.1093/annonc/mdh432
    Search in Google Scholar
  16. [16] Heitz F, PH, Traut A, Lueck HJ, Beutel B, du Bois A. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol 2008; 26: (Abstr 1010).10.1200/jco.2008.26.15_suppl.1010
    Search in Google Scholar
  17. [17] Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009; 20:621-627.10.1093/annonc/mdn682
    Search in Google Scholar
  18. [18] Di Stefano A, Yong Yap Y, Hortobayi GN, George R. The natural history of breast cancer patients with brain metastases. Cancer 1979;44:1913-1918.10.1002/1097-0142(197911)44:5<;1913::AID-CNCR2820440554>3.0.CO;2-D
    Search in Google Scholar
  19. [19] Bachmann C, Schmidt S, Staebler A, Schittenhelm J, Wallwiener D, Grischke EM. Risk factors and survival outcome in cerebral metastatic breast cancer. Med Oncol. 2014 Mar;31(3):862.10.1007/s12032-014-0862-2
    Search in Google Scholar
  20. [20] Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A et al. Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 22:3302-3308, 2004
    Search in Google Scholar
  21. [21] Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983;52:2349-2354.10.1002/1097-0142(19831215)52:12<;2349::AID-CNCR2820521231>3.0.CO;2-B
    Search in Google Scholar
  22. [22] Arslan C, Dizdar O, Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother, 2010, 11, 1089-1100.10.1517/14656561003702412
    Search in Google Scholar
  23. [23] Wen PY, Shafman TD. Site-specific therapy of metastatic breast cancer. In: Harris JR, ed. Disease of the Breast. Philadelphia: Lippincott Williams & Wilkins, 2000:841-853.
    Search in Google Scholar
  24. [24] Rubinstein AB, Schein M, Reichenthal E. The association of carcinoma of the breast with meningioma. Surg Gynecol Obstet 1989;169:334-336.
    Search in Google Scholar
  25. [25] Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 1975;25:705-712.10.1212/WNL.25.8.705
    Search in Google Scholar
  26. [26] Peretti-Viton P, Margain D, Murayama N, Kadr I, Peragut JC. Brain metastases. J Neuroradiol 1991;18:161-172.
    Search in Google Scholar
  27. [27] Chang EL, Hassenbusch SJ, Shiu A, Lang FF, Allen PK, Sawaya R et al. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases. Neurosurgery 2003;53:272-281.10.1227/01.NEU.0000073546.61154.9A
    Search in Google Scholar
  28. [28] Loeffler J, Alexander E. Radiosurgery for the treatment of intracranial metastases. In: Loeffler JS, ed. Stereotactic Radiosurgery. New York: McGraw- Hill, 1993:197-206.
    Search in Google Scholar
  29. [29] Order SE, Hellman S, Von Essen CF, Kligerman MM. Improvement in quality of survival following wholebrain irradiation for brain metastasis. Radiology 1968;91:149-153.10.1148/91.1.149
    Search in Google Scholar
  30. [30] West J, Maor M. Intracranial metastases: behavioral patterns related to primary site and results of treatment by whole brain irradiation. Int J Radiat Oncol Biol Phys 1980;6:11-15.10.1016/0360-3016(80)90196-0
    Search in Google Scholar
  31. [31] DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fuks Z et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 1989;24:798-80510.1227/00006123-198906000-000022473409
    Search in Google Scholar
  32. [32] Loeffler JS, Kooy HM, Wen PY, Fine HA, Cheng CW, Mannarino EG et al. The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol 1990;8:576-582.10.1200/JCO.1990.8.4.5762179476
    Search in Google Scholar
  33. [33] Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000; 18:2349-2351.10.1200/JCO.2000.18.11.234910829059
    Search in Google Scholar
  34. [34] Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CL. Effects of the EGFR/HER2 kinase inhibitor W572016 on EGFR- and HER2- overexpressing breast cancer cell line Proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58:344-352, 200410.1016/j.ijrobp.2003.09.04614751502
    Search in Google Scholar
  35. [35] Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011;22 (3): 625-630.10.1093/annonc/mdq43420724575
    Search in Google Scholar
  36. [36] Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab- Refractory Metastatic Breast Cancer JCO March 1, 2010 vol. 28 no. 7 1124-113010.1200/JCO.2008.21.443720124187
    Search in Google Scholar
  37. [37] Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom K,Fehrenbacher L, et al. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer JCO February 1, 2005 vol. 23 no. 4 792-79910.1200/JCO.2005.05.09815681523
    Search in Google Scholar
  38. [38] Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, et al. Phase II study of temozolamide in heavily ptretreated cancer patients with brain metastases. Annals of Oncology 2001;12:249-251.10.1023/A:1008354323167
    Search in Google Scholar
  39. [39] Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol. 2006;17:952-6.10.1093/annonc/mdl05616565212
    Search in Google Scholar
  40. [40] Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neurooncol. 2005;71:61-5.10.1007/s11060-004-9176-015719277
    Search in Google Scholar
  41. [41] Okuda H, Xing F, Pandey PR, Sharma S, Watabe M, Pai SK, et al. miR-7 suppresses brain metastasis of breast cancer stem like cells by modulating KLF-4. Cancer Res. 2013;73(4):1434-44.10.1158/0008-5472.CAN-12-2037357613823384942
    Search in Google Scholar
  42. [42] Alsidawi S, Malek E and Driscoll J. MicroRNAs in Brain Metastases: Potential Role as Diagnostics and Therapeutics. Int. J. Mol. Sci. 2014;15: 10508-10526.
    Search in Google Scholar
  43. [43] Zhang S, Huang WC, Zhang L, Cancer Brain Metastases Src Family Kinases as Novel Therapeutic Targets to Treat Breast. Cancer Res. 2013;73:5764-5774.10.1158/0008-5472.CAN-12-1803378159223913825
    Search in Google Scholar
  44. [44] Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, et al. The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis. Sci Transl Med. 2013;180(5):180ra48.10.1126/scitranslmed.3005109386390923576814
    Search in Google Scholar
  45. [45] https://clinicaltrials.gov/ct2/results?term=breast+ca ncer+and+brain+metastases&recr=Open&pg=1
    Search in Google Scholar
DOI: https://doi.org/10.1515/fco-2015-0004 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 18 - 26
Published on: Mar 25, 2015
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Breast cancer,
Brain metastases,
Long-term survival
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2015 Aravantinou-Fatorou E, Skarlos D, Klouvas G, Galani E, Christodoulou C., published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 6 (2015): Issue 1 (March 2015)Next article